BSX Looks 59.8% Undervalued on GF Value™ with Strong 80/100 GF S
Citi downgraded Boston Scientific (BSX) to Neutral, lowering its price target to $50 from $57, citing operational challenges and competitive pressures. GF Value™ suggests BSX is 59.8% undervalued at $43.14, with a strong GF Score™ of 80/100. Insiders have net sold shares, while 19 gurus hold the stock, with mixed activity.
How this was made
The 30-second read
Why it matters
Analyst downgrade may trigger sell‑offs, but the company's strong fundamentals and valuation gap could attract contrarian buyers.
Market read
The downgrade provides fresh actionable insight for traders monitoring US med‑tech equities.
What to watch
Strong GF Score and profitability metrics indicate resilience despite short‑term setbacks.
Background
Boston Scientific is a leading medical‑device maker; recent cyberattack disrupted operations and competition intensified.
Ticker impact
Citi downgraded Boston Scientific (BSX) to Neutral and cut the price target to $50, citing an August cyberattack and rising competition.
Potential short‑term decline of 5‑10% as investors reassess risk.
Analyst downgrade with a lower target typically triggers sell pressure, especially given operational setbacks.
Market effects
May weigh on other medical‑device peers as cyber risk and competition concerns rise.
US healthcare sector could see modest pullback.
Limited to investors tracking US med‑tech stocks.
Counterpoint
The 59.8% valuation gap suggests a deep discount that could be a buying opportunity if the cyberattack impact is temporary.
Key entities
- analystCiti
Downgraded BSX to Neutral and lowered price target.
- companyBoston Scientific Corp
Subject of downgrade; facing cyberattack fallout and competitive pressure.
